SBHMY (Sino Biopharmaceutical) Long-Term Capital Lease Obligation : $11 Mil (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Sino Biopharmaceutical Long-Term Capital Lease Obligation?

Sino Biopharmaceutical's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2024 was $11 Mil.

Sino Biopharmaceutical's quarterly Long-Term Capital Lease Obligation declined from Dec. 2023 ($42 Mil) to Jun. 2024 ($21 Mil) and declined from Jun. 2024 ($21 Mil) to Dec. 2024 ($11 Mil).

Sino Biopharmaceutical's annual Long-Term Capital Lease Obligation declined from Dec. 2022 ($47 Mil) to Dec. 2023 ($42 Mil) and declined from Dec. 2023 ($42 Mil) to Dec. 2024 ($11 Mil).

Sino Biopharmaceutical Long-Term Capital Lease Obligation Historical Data

The historical data trend for Sino Biopharmaceutical's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Long-Term Capital Lease Obligation Chart

Sino Biopharmaceutical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

40.50

50.23

46.51

41.79

11.45

Sino Biopharmaceutical Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															46.51	45.98	41.79	21.32	11.45

Sino Biopharmaceutical (OTCPK:SBHMY) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Sino Biopharmaceutical Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Sino Biopharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (OTCPK:SBHMY) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

SBMFF:USA 01177:Hong Kong SMZ1:Germany

Address

1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website

https://www.sinobiopharm.com

Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2024, 41.8% of the firm's total revenue comes from its innovative product category, which includes innovative drugs and biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 37.2% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.